Translating tolerogenic therapies to the clinic – where do we stand? by Fadi Issa & Kathryn J. Wood
“ﬁmmu-03-00254” — 2012/8/18 — 16:15 — page 1 — #1
REVIEW ARTICLE
published: 20 August 2012
doi: 10.3389/ﬁmmu.2012.00254
Translating tolerogenic therapies to the clinic – where
do we stand?
Fadi Issa and Kathryn J.Wood*
Transplantation Research Immunology Group, Nufﬁeld Department of Surgical Sciences, Level 6, John Radcliffe Hospital, University of Oxford, Oxford, UK
Edited by:
Stephen Paul Cobbold, University of
Oxford, UK
Reviewed by:
Ani Chandraker, Brigham and
Women’s Hospital, USA
Alf Hamann, Charite University
Medicine and German Rheumatism
Research Center Berlin, Germany
*Correspondence:
Kathryn J.Wood, Transplantation
Research Immunology Group,
Nufﬁeld Department of Surgical
Sciences, Level 6, John Radcliffe
Hospital, University of Oxford,
Oxford OX3 9DU, UK.
e-mail: kathryn.wood@nds.ox.ac.uk
Manipulation of the immune system to prevent the development of a speciﬁc immune
response is an ideal strategy to improve outcomes after transplantation. A number of
experimental techniques exploiting central and peripheral tolerance mechanisms have
demonstrated success, leading to the ﬁrst early phase clinical trials for tolerance induc-
tion.The ﬁrst major strategy centers on the facilitation of donor-cell mixed chimerism in the
transplant recipient with the use of bone marrow or hematopoietic stem cell transplanta-
tion. The second strategy, utilizing peripheral regulatory mechanisms, focuses on cellular
therapy with regulatory T cells. This review examines the key studies and novel research
directions in the ﬁeld of immunological tolerance.
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INTRODUCTION
Strategies to prevent the development of a speciﬁc immune
response are invaluable in the quest to achieve improved out-
comes after solid organ transplantation (SOT), bone marrow and
hematopoietic stem cell transplantation (BMT; HSCT), as well
as for the treatment of autoimmune diseases. Speciﬁc immune
unresponsiveness is the hallmark of clinical tolerance, which in
turn may be deﬁned as the long-term survival of an allograft with
normal function and no evidence for rejection, in the absence of
immunosuppressive drug therapy. The quest for tolerance began
with the landmark paper by Billingham et al. (1953), in which
tolerance was induced to a mouse skin allograft by injection of
a recipient mouse with donor-derived F1 cells as a neonate. Cur-
rent experimental and early clinical strategies to promote tolerance
center on the induction of central tolerance by deletion of donor-
reactive leukocytes, most commonly the induction of chimerism,
or on peripheral tolerance, most commonly the induction or
expansion of regulatory T cells (Treg; Wood et al., 2012).
CHIMERISM
During T cell development in the thymus, T cells with T cell recep-
tors (TCRs) that are strongly reactive to host MHC molecules
are deleted by a process termed negative selection (i.e., central
deletion). This physiological process has been harnessed experi-
mentally for the induction of tolerance to foreign antigens. The
method used by Medawar to achieve tolerance to skin allografts
over 60 years ago was in a fortunate strain combination with
only a class I MHC mismatch (Billingham et al., 1953). More
recently, similar methods have been used to achieve “central
deletion” in fully MHC-mismatched models of transplantation
(Cober et al., 1999; Butler et al., 2000; Petit et al., 2004; Mathes
et al., 2005). Nevertheless, such strategies are neither consistently
successful nor easily translatable to the clinic. Alternatively,
hematopoietic complete chimerism through myeloablative ther-
apy and donor-derived bone marrow transplantation results in the
repopulation of the host thymus with donor-type dendritic cells
(DCs) that delete donor-reactive T cells. Complete chimerism is
the replacement of all host hematopoietic cells with donor-derived
stem cells such as hematopoietic stem cells (HSCs). Because
such donor-derived stem cells have the ability to replicate per-
petually, they theoretically continue to provide donor-type DCs
indeﬁnitely.
A number of successful clinical cases in SOThave been reported
whereby patients with hematological indications for bone mar-
row ablation who also require renal transplantation have received
a BMT and a kidney transplant from the same donor, resulting
in long-term donor-speciﬁc tolerance (Buhler et al., 2002; Fud-
aba et al., 2006; Spitzer et al., 2011). Nevertheless, the morbidity
and mortality of myeloablative therapy and risk of graft-versus-
host disease (GvHD) in most transplant recipients makes this
mode of therapy unacceptable to those without a hematological
indication for bone marrow ablation. On the other hand, mixed
chimerism, where donor cells represent a varying proportion (but
not 100%) of the total hematopoietic pool is a more promis-
ing area of research (Kawai et al., 2011). Mixed chimerism can
be established using non-myeloablative conditioning regimens,
therefore maintaining immunocompetence and reducing the risk
of GvHD (Figure 1).
There is evidence for the operation of both central dele-
tional and peripheral regulatory mechanisms in mixed chimerism
(Pilat and Wekerle, 2010; Sachs et al., 2011). In models where
mixed chimerism is induced following total body irradiation
(TBI), the speciﬁc depletion of donor cells is associated with
the appearance of donor-reactive T cells in the periphery and
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FIGURE 1 | Development of tolerance through mixed chimerism.
A conditioning regimen is administered which consists of a combination of
drugs (occasionally together with irradiation) to allow the engraftment of
allogeneic bone marrow (BM) or hematopoietic stem cells (HSCs). A bone
marrow transplant (BMT) or hematopoietic stem cell transplant (HSCT) is
given to the patient. The donor HSCs seed into the recipient’s BM niches
together with the recipient’s HSCs, providing a self-renewing source of donor
and recipient hematopoietic cells, leading to widespread multilineage mixed
chimerism. Donor dendritic cells seed the thymus, and together with
recipient dendritic cells, mediate central clonal deletion of newly developing
donor-reactive and recipient-reactive thymocytes. Peripheral regulation also
takes place whereby newly developing donor-reactive and recipient-reactive
T cells that escape negative selection in the thymus are suppressed in the
periphery by regulatory T cells (Treg).
the loss of tolerance (Khan et al., 1996). This loss of tolerance
may be avoided by removal of the thymus before depletion
of donor cells, highlighting the importance of the intrathymic
chimerism in the maintenance of tolerance. In less intensive
conditioning mechanisms where costimulatory blockade is used
to facilitate mixed chimerism, intrathymic deletion remains an
important mechanism contributing to tolerance and there is no
evidence of a role for Treg (Wekerle et al., 2000; Fehr et al., 2008).
Nevertheless, regimens that produce less complete deletion of
pre-existing donor-reactive T cells may be dependent on periph-
eral tolerance mechanisms. For example, in a costimulation-based
non-myeloablative BMT model, depletion of CD25+ cells at the
time of BMT prevents the induction of tolerance (Bigenzahn et al.,
2005). CD4+ T cells isolated from these chimeras display reg-
ulatory capabilities. In another model, the challenge of mixed
chimeras with naïve T cells does not lead to the rejection of skin
allografts, suggesting a role for peripheral regulatory mechanisms
(Domenig et al., 2005). Moreover, mixed chimerism induction
techniques that actively employperipheral regulation, for example,
by the infusion of Treg, may facilitate the development of mixed
chimerism and lead to more robust tolerance (Seung et al., 2003;
Pilat et al., 2010).
A series of promising clinical trials for SOT utilizing mixed
chimerism for the induction of tolerance have been performed.
An initial trial enrolled six patients with renal failure consequent
to multiple myeloma (Fudaba et al., 2006). Patients received non-
myeloablative BMTs and renal transplants from an HLA-identical
sibling followed by a donor leukocyte infusion as treatment for
both the multiple myeloma and renal failure. Four patients tran-
siently developed mixed chimerism, which was later lost, while
the other two patients eventually developed full donor chimerism.
Interestingly, all patients successfully accepted their renal trans-
plants long-term (up to >9 years) without any immunosuppres-
sion. Following this study, a similar approach was piloted in ﬁve
patients without a hematological malignancy (Kawai et al., 2008;
LoCascio et al., 2010). Patients received an HLA-mismatched hap-
loidentical bone marrow transplant along with a renal transplant
from the same donor. All patients developed transient mixed
chimerism, but this was lost after day 21. Four patients in the trial
currently maintain graft function after weaning from their initial
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immunosuppression (follow-up 2–5 years post-weaning). How-
ever, one kidney graft was lost due to acute antibody-mediated
rejection, leading to a modiﬁcation in the trial protocol to include
B cell depletion with rituximab.
In another recent proof-of-concept study, 12 living donor
HLA-matched kidney transplant recipients received a donor-cell
infusion of 5–16 × 106/kg CD34+ cells mixed with 1–10 × 106/kg
CD3+ T cells after conditioning with total lymphoid irradia-
tion and ﬁve doses of rabbit antithymocyte globulin (Scandling
et al., 2011), as per a protocol previously reported as a case
report (Scandling et al., 2008). None of the patients developed
GvHD. In 8 of the 12 patients, maintenance immunosuppres-
sion was eventually discontinued and patients have since been
immunosuppression-free with good graft function and without
evidence of acute or chronic rejection (follow-up 12–36 months).
The remaining four patients experienced rejection episodes on
weaning from immunosuppression and have therefore remained
on immunosuppression. The authors now plan to apply the pro-
tocol to HLA-mismatched transplant recipients. Given the notable
immunosuppression-free success rate and safety proﬁle, it will be
interesting to observe the efﬁcacy of the protocol in this situation.
A recent Phase II clinical trial investigated the use of HSCT
together with a facilitating cell (FC) infusion to promote the
development of chimerism and subsequent tolerance in eight
HLA-mismatched living donor renal transplant recipients (Leven-
thal et al., 2012). FCs were deﬁned as CD8+ bone marrow-derived
cells that did not express the TCR and primarily contained a
plasmacytoid DC population (Kaufman et al., 1994; Grimes et al.,
2004; Fugier-Vivier et al., 2005). In this clinical trial, combined FC
and HSCT transplantation initially led to high levels of chimerism
in all eight renal allograft recipients. Five of the recipients displayed
stable chimerism and donor-speciﬁc tolerance and were subse-
quently weaned off maintenance immunosuppression one year
post-transplant. Two patients developed only transient chimerism
and were therefore maintained on low-dose tacrolimus monother-
apy. One patient, although displaying robust chimerism, devel-
oped viral sepsis 2 months post-transplantation and subsequently
lost the kidney graft due to renal artery thrombosis. Immuno-
logical monitoring of the patients enrolled in the trial showed a
signiﬁcant reduction in circulatingCD4+ but notCD8+ cells post-
transplantation. The signiﬁcance of this observation is unclear,
however it may be indicative of central deletion of alloreactive
CD4+ T cells or peripheral regulation by Treg. Indeed, an increase
in the Treg to effector T cell ratio was observed in chimeric recip-
ients but not those that achieved only transient macrochimerism.
While the above approaches have demonstrated some success
in living donor transplants, the induction of mixed chimerism
in recipients of cadaveric organ transplants may prove more
challenging. BMT has only been trialed on a small scale in cadav-
eric donor transplants, principally in the context of vascularized
composite allograft (VCA) transplants. The ﬁrst face transplant
performed in France used a post-transplant donor-derived bone
marrow infusion, although it does not appear that this approach
accorded any clear beneﬁt in terms of a reduction in episodes of
rejection (Hequet et al., 2008). Furthermore, microchimerism was
only detectable at a single point 2 months post-operatively and not
thereafter (Hequet et al., 2008). Since then, ﬁve VCA transplants
performed in Pittsburgh have employed the “Pittsburgh Proto-
col” in which a bone marrow infusion is given within 15 days of
VCA transplantation (International Hand and Composite Tissue
Allotransplantation Society Congress, Atlanta 2011). Early reports
indicate that patients treated in this manner have been maintained
successfully on single drug immunosuppression with tacrolimus.
Interestingly, the presence of vascularized bone marrow in
many VCA transplants raises the possibility that chimerism may
develop by nature of the simultaneous transplantation of HSCs
within theVCA. To this end, various rat models of hindlimb trans-
plantationusingT cell depleting antibody alongwith immunosup-
pression have achieved long-term allograft survival (Siemionow
et al., 2002a,b, 2003; Ozer et al., 2003, 2004; Siemionow and Klim-
czak, 2009), although mixed chimerism is not always readily
detectable (Quatra et al., 2006). In these models, the bone mar-
row component of the VCA transplant is critical to the attainment
of mixed chimerism and long-term allograft survival (Siemionow
et al., 2005; Siemionow, 2011). Moreover, increased levels of
chimerism are detectable with larger sized VCA allografts in rats,
indicating the role of the transplant in providing donor cells
(Nasir et al., 2008). In a rat model of facial allograft transplan-
tation, mixed macrochimerism has been observed with the use
of only cyclosporine monotherapy (Demir et al., 2004; Kulahci
et al., 2010). Mixed chimerism has also been achieved using
non-depleting CD4+ blockade and depleting CD8+ antibody in
conjunction with rapamycin and α-CD154 costimulatory block-
ade, without a bone marrow transplant, relying on bone marrow
in a mouse hindlimb VCA to provide donor cells for chimerism
(Li et al., 2008). In general, clinical data have not been particularly
encouraging, with no evidence for the development of chimerism
in VCA transplantation. This may be due to only small amounts
of bone marrow being transferred that have limited functionality
in the adult (Granger et al., 2002; Petruzzo et al., 2003). Moreover,
there is experimental evidence that the recipient thymus is neces-
sary for peripheral chimerism to develop after transplantation of a
bone marrow-containingVCA (Li et al., 2007). In humans the thy-
mus involutes and becomes atrophic after puberty and is therefore
less likely to support the development of chimerism. It is impor-
tant to note that in theory, chimerism is a double-edged sword,
whereby the greater the likelihood of chimerism, the greater the
anti-host alloresponse and risk of GvHD (Wood, 2003).
REGULATORY T CELLS
While the methods described above relate to exploiting the natural
mechanisms used by the immune system to ensure self-tolerance
through centralmechanisms, several peripheral regulatorymecha-
nisms also exist as a fail safe mechanism to maintain self-tolerance
and to prevent an overshoot of the normal immune response (Issa
and Wood, 2010; Wood and Goto, 2012). While most autoreac-
tive cells are deleted centrally in the thymus, some autoreactive
T cells escape this process and require peripheral regulation to
prevent autoimmunity. CD4+ Treg are central to these mecha-
nisms. Scurfy mice lacking the Treg-speciﬁc transcription factor
forkhead box P3 (foxp3) develop a lymphoproliferative disorder
(Brunkow et al., 2001) and humans with mutations in FOXP3
can develop IPEX (immunodysregulation, polyendocrinopathy,
and enteropathy, X-linked; Bennett et al., 2001). FOXP3 is closely
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linked to suppressive activity and its sustained expression is
required for the maintenance of regulatory activity (Josefowicz
and Rudensky, 2009).
Treg can be divided into thymus-derived naturally occurring
CD4+CD25hiFOXP3+ Treg (nTreg or tTreg; Hori et al., 2003) and
induced or adaptive CD4+ Treg (iTreg), which upregulate FOXP3
in the periphery under deﬁned conditions of antigen-exposure,
for example, in the presence of transforming growth factor β
(TGFβ; Kingsley et al., 2002; Karim et al., 2004, 2005). Type 1
Treg (Tr1) cells are a distinct population of peripherally induced
Treg that develop in the presence of IL-10 and regulate responses
through FOXP3-independent secretion of IL-10 and TGFβ, lead-
ing to bystander regulation of effector T cells (Battaglia et al.,
2006a). nTreg represent 5–10% of the peripheral CD4+ pool and
constitutively express high levels of surface CD25 although this
is not a reliable marker due to its upregulation on recently acti-
vated T cells. Nevertheless, although CD25 appears on recently
activated CD4+ T cells, some of these are true proliferating Treg.
For example, during the secondary antigenic response that devel-
ops after human tuberculin puriﬁed protein derivative is injected
into skin, CD4+CD25+ cells proliferate within the skin. Many of
these proliferating cells are in fact FOXP3+ and display functional
and phenotypic markers of Treg (Vukmanovic-Stejic et al., 2008).
It is unclear how much of the peripheral CD4+ population iTreg
represent, but given that these cells are induced in speciﬁc inﬂam-
matory environments it is likely that their number is location and
time-dependent.
In transplantation, both direct and indirect allorecognition
contribute to the immune response that results in graft destruc-
tion. However, with time after transplantation, passenger antigen-
presenting cells are lost and organ parenchyma is less able to
stimulate the host via the direct pathway. The indirect allore-
sponse therefore becomes of increasing importance and may be
more relevant in chronic rejection (Baker et al., 2001). Interest-
ingly, alloreactive T cells that respond by the indirect pathway are
more resistant to inhibition by conventional immunosuppression
and are detectable in the peripheral blood of transplant recipients
years after transplantation (Sawyer et al., 1993; Vella et al., 1997).
The alloreactivity of Treg may therefore be important in determin-
ing their ability to promote tolerance. Indeed, Treg that are both
directly and indirectly alloreactive are able to prevent both acute
and chronic rejection in mice, whereas those that are only directly
alloreactive appear to only be able to prevent acute rejection (Joffre
et al., 2008; Tsang et al., 2008).
Studies assessing the potential of nTreg, iTreg, and Tr1 cells to
promote allograft survival in experimental transplantation have
yielded promising results to date. In these studies Treg may be
induced in vivo by employing costimulatory blockade or lympho-
cyte depletion around the time of transplantation, often together
with an antigen challenge (Cobbold et al., 1986; Qin et al., 1993;
Graca et al., 2000; Kingsley et al., 2007; Francis et al., 2011).
Alternatively nTreg may be expanded ex vivo or converted from
non-Treg cell types to iTreg in vitro.
EX VIVO EXPANSION
Human Treg for cell therapy protocols are produced by isola-
tion of cells from peripheral or umbilical cord blood (UCB) and
subsequent ex vivo expansion or direct use in vivo. In order to
isolate Treg efﬁciently and to a high purity, reliable markers of
identiﬁcation are required. Given the non-exclusivity of CD25
and FOXP3 expression, a number of other markers are in use. Of
these, CD127 (the IL-7 receptor α-chain), CD49b (the α-chain
of the integrin VLA-4 – a4b1), CD45RA, and latency-associated
peptide (LAP) are particularly useful. Other Treg markers include
CD152 (CTLA-4), GITR, CD69, and CD44 but these are less use-
ful as they may also be expressed in almost identical patterns on
non-regulatory activated T cells.
The use of the low expression of CD127 for the isolation of
Treg was described approximately 5 years ago (Liu et al., 2006;
Seddiki et al., 2006; Putnam et al., 2009) and is particularly help-
ful as it deﬁnes a highly suppressive population of Treg. In a
humanized mouse model of vessel allograft rejection, human ex
vivo-expanded CD25hiCD4+ orCD127loCD25+CD4+ nTregwere
used to modulate immune responses in vivo to reduce neointimal
expansion. Treg expressing low levels of CD127 were found to be
ﬁve timesmore potent than those expressing only CD25. The same
population of CD127loTreg have been shown to be active in the
prevention of human skin graft rejection in a similar humanized
mouse model (Issa et al., 2010). The absence of CD49b is another
helpful marker for Treg identiﬁcation, as together with CD127 it
allows forTreg isolationbynegative selection alone (Kleinewietfeld
et al., 2009).
CD45RA allows cells to be divided into CD25+CD45RA+
FOXP3lo (resting naïve Treg), CD25hiCD45RA−FOXP3hi (acti-
vated Treg), and CD25+CD45RA−FOXP3lo (non-suppressive T
cells) populations (Miyara et al., 2009). Resting naïve and acti-
vated Treg are both suppressive in vitro, whilst only resting naïve
Treg proliferate in vivo and evolve into suppressive CD45RA−Treg.
UCBcontains a highnumber of naïveCD45RA+ cells, and is there-
fore an attractive source of resting naïve Treg (Riley et al., 2009).
However, UCB Treg are low in frequency and require either in
vitro culture or pooling of multiple blood units. Furthermore, as
UCB Treg are allogeneic to both the donor and recipient they are
likely to be subject to an alloresponse therefore complicating their
in vivo use.
LAP has been shown to deﬁne a population of Treg that express
high levels of foxp3, secrete immunosuppressiveTGFβ, and exhibit
enhanced in vivo regulatory activity (Chen et al., 2008). More-
over, LAP itself is functionally suppressive independent of TGFβ
(Ali et al., 2008). In Treg expansion cultures, the expression of
LAP allows the distinction and selection of activated Treg from
activated non-Treg cell types (Tran et al., 2009).
Ex vivo expansion of isolated Treg is largely performed by
stimulation with αCD3/αCD28 microbeads in the presence of
recombinant human (rh) IL-2 (Sagoo et al., 2008; Trzonkowski
et al., 2009). The non-speciﬁc TCR stimulation in this system
leads to the production of a polyclonally reactive population of
Treg. Donor alloantigen-reactive Treg that have been expanded
in the presence of donor-derived APC have been shown to
be more potent suppressors in vitro and in vivo than poly-
clonally reactive Treg, and their speciﬁc reactivity implies that
they are safer for in vivo use (Golshayan et al., 2007; Sagoo
et al., 2011). Selection of alloantigen-stimulated Treg from a cul-
ture where allogeneic stimulators are used may be possible by
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enrichment of Treg that co-express the activation markers CD69
and CD71 (Sagoo et al., 2011; J. Hester and K.J. Wood, unpub-
lished data). Other methods for the production of alloantigen-
reactive Treg include retroviral vector transduction of Treg with
genes that encode for TCRs with known antigen speciﬁcities
(Jiang et al., 2006).
IN VIVO INDUCTION
In vivo approaches are based on increasing the frequency or
potency of Treg by exposure to antigen, inducing an expan-
sion of nTreg or converting non-Treg to iTreg (Long and Wood,
2009; Francis et al., 2011). Treg may be generated in vivo by
pre-treating mice with a donor alloantigen (in the form of a
donor-speciﬁc transfusion) along with a non-depleting α-CD4
mAb (Kingsley et al., 2002, 2007). Treg produced in this man-
ner are capable of preventing allograft rejection in vivo (Wood
et al., 1991; Bushell et al., 1994, 1995; Saitovitch et al., 1995, 1996,
1997; Kingsley et al., 2002, 2007; Bushell et al., 2003; Karim et al.,
2005; Warnecke et al., 2007). While this tolerance appears to be
antigen-speciﬁc in nature, another “boosting” blood transfusion
allows tolerance to develop to a third-party allograft (Karim et al.,
2005). CD4+CD25+ Treg isolated from these animals may pre-
vent allograft rejection in naïve mice by adoptive transfer (Hara
et al., 2001; Kingsley et al., 2002) and are able to prevent skin
graft rejection initiated by both CD4+ (Hara et al., 2001; Gol-
shayan et al., 2007) and CD8+ (van Maurik et al., 2002; Jones
et al., 2010) T cells. Alternatively, costimulatory blockade or
lymphocyte depletion using monoclonal antibodies around the
time of transplantation may also promote tolerance induction
(Qin et al., 1990; Qin et al., 1993; Graca et al., 2000; Waldmann
et al., 2006). Interestingly, even nTreg isolated from naïve ani-
mals may prevent rejection, although 10-fold more such Treg
are required to attain long-term allograft survival compared to
Treg isolated from tolerant mice treated with antigen exposure
(Graca et al., 2002). The folate receptor 4 (FR4) allows the iden-
tiﬁcation of these alloantigen-stimulated Treg (Yamaguchi et al.,
2007). Alloantigen-stimulated FR4high Treg are signiﬁcantly more
effective at prolonging mouse skin allograft survival compared to
FR4intermediate Treg.
Another method for in vivo generation is the injection of IL-
2-IL-2 mAb complexes into mice, resulting in an over 10-fold
expansion of Treg in vivo. Animals treated by this method are
resistant to experimental autoimmune encephalomyelitis (EAE)
induction and display tolerance to islet allografts (Webster et al.,
2009). Injectionof IL-2-IL-2mAbcomplexes togetherwith recom-
binant granulocyte-colony stimulating factor (G-CSF) induces
expansion of Treg and myeloid-derived suppressor cells (MDSCs)
in vivo, promoting mouse skin allograft survival in MHC Class
II-mismatched models (Adeegbe et al., 2010).
There has been a great deal of discussion regarding the func-
tional stability of Treg. Zhou et al. (2009) demonstrated that some
Treg lose foxp3 (becoming exfoxp3 cells), developing an activated
memory-type phenotype, and are pathogenic in vivo. This loss
of foxp3 was linked to a proinﬂammatory microenvironment in
which Treg acquire an effector T cell phenotype, secreting IL-17
and interferon γ (IFNγ; Yang et al., 2008; Ayyoub et al., 2009;
Komatsu et al., 2009; Voo et al., 2009; Chadha et al., 2011).
Importantly, Treg may not be particularly effective at suppress-
ing IL-17 producing T cells (Heidt et al., 2010; Zhang et al., 2010;
Chadha et al., 2011), although data fromour own studies in kidney
transplant patients treated with the leukocyte depleting mono-
clonal antibody alemtuzumab (Campath or anti-CD52 antibody)
suggest that Treg present in these patients can regulate Th17 cells
(Hester et al., 2011). Stability of Treg is important to consider in
transplantation as there is evidence that Treg transfer into lym-
phopaenic mice may result in the loss of foxp3 expression in up
to 50% of the adoptively transferred cells (Duarte et al., 2009).
This is a particularly important point to consider if Treg cellular
therapy is to be employed in patients who are lymphopaenic post-
immunosuppressive induction therapy. However, a recent study
by Miyao et al. (2012) has elegantly demonstrated that the plas-
ticity of Treg is due to only a minor population of foxp3+ cells.
In this study, suppressive foxp3+Treg do not develop effector cell
function even in inﬂammatory or lymphopaenic environments.
While such Treg may transiently lose foxp3 expression, on activa-
tion foxp3 is re-expressed and suppressive capabilities return. It is
therefore only a small minority (2–3%) of the peripheral foxp3+
pool which are originally non-regulatory and which may then lose
foxp3 to become pathogenic. Overgrowth of this small population
may explain previous data demonstrating the plasticity of Treg.
Importantly in this study, it is epigenetic control of Foxp3 that
dictates whether foxp3+ cells are true Treg. Demethylation of the
Treg cell-speciﬁc demethylated region (TSDR) indicates that cells
are committed suppressive Treg, regardless of the ongoing expres-
sion of foxp3. Identiﬁcation of the methylation status of the TSDR
is therefore a valuable indicator of the purity of cell preparations
produced for clinical use.
REGULATORY B CELLS
There are multiple reports of clinical operational tolerance, or
long-term functioning allograft survival in the absence of any
immunosuppression. This has most commonly been observed
in liver transplantation (Lerut and Sanchez-Fueyo, 2006) but has
also been reported in a small number of renal transplant recipi-
ents (Orlando et al., 2010). In a study where the immune proﬁle
of tolerant renal transplant recipients was analyzed, the most
striking feature was a bias towards a differential expression of B
cell-related genes and an expansion of peripheral blood B cells
in tolerant patients (Newell et al., 2010; Sagoo et al., 2010). This
latter observation raises the interesting possibility that regula-
tory B cells (Bregs) may be playing a role. Bregs express high
levels of CD1d, CD21, CD24, and IgM, have an immature or
transitional phenotype, and are active through the secretion of
suppressive IL-10 (Mauri and Blair, 2010). IL-10-secreting B cells
have been shown to regulate autoimmune responses in vivo (Fil-
latreau et al., 2002; Mauri et al., 2003). There are currently no
clinical studies examining Bregs as a cellular therapy. Further work
is required to determine the optimal methods for the production
of a functionally suppressive population of Bregs that may be used
clinically.
DENDRITIC CELLS
While DCs are known to be pivotal in the development of the
alloresponse, some populations of DCs may also be active in the
www.frontiersin.org August 2012 | Volume 3 | Article 254 | 5
“ﬁmmu-03-00254” — 2012/8/18 — 16:15 — page 6 — #6
Issa andWood Tolerogenic therapies
promotion of tolerance (Morelli and Thomson, 2007; van Kooten
et al., 2011). Immature myeloid-derived DCs have been shown to
promote the survival of heart allografts in a donor-speciﬁc man-
ner (Lutz et al., 2000) and regulatory DCs with low costimulatory
ability may prevent the development of GvHD in mice (Sato et al.,
2003). However, evenmatureDCs expressing normal or high levels
of MHC and costimulatory molecules may promote the develop-
ment of tolerance. These DCs prime CD4+ and CD8+ T cells that
in turn develop regulatory activity in vitro (Albert et al., 2001; Ver-
hasselt et al., 2004). In vivo, myeloid-derived DCs matured with
tumor necrosis factor α (TNFα) and expressing high levels of
MHC II are able to protect mice from CD4+ T cell-mediated EAE
(Menges et al., 2002).
The tolerogenic effects of DCs can be potentiated by the
administration of costimulatory blockade agents. For example,
plasmacytoid DCs have been shown to promote the induction
of IL-10-secreting Treg and may promote heart allograft sur-
vival in vivo (Gilliet and Liu, 2002; Abe et al., 2005). However,
with the addition of anti-CD154 antibody, this effect is sig-
niﬁcantly enhanced (Bjorck et al., 2005). A similar effect may
be observed with the administration of costimulatory blockade
with immature myeloid-derived DCs (Lu et al., 1997). Plas-
macytoid DCs may also be important in facilitating mixed
chimerism as described earlier when in the form of FCs (Kauf-
man et al., 1994; Grimes et al., 2004; Fugier-Vivier et al., 2005;
Leventhal et al., 2012). Importantly, FCs have been demon-
strated to promote the generation of Treg and prevent GvHD
development inmice (Colson et al., 2004; Taylor et al., 2007;Huang
et al., 2011).
MYELOID-DERIVED SUPPRESSOR CELLS AND
REGULATORY MACROPHAGES
Myeloid-derived suppressor cells are a heterogeneous population
of cells with both innate and adaptive immune targets, which
include T, B and NK cells (Boros et al., 2010). Common pheno-
typic markers among MDSCs include GR1 and CD11b in mice
and CD33, CD11b, CD34, and low MHC Class II expression
in humans. Experimentally, mouse MDSCs induced by cos-
timulatory blockade in vivo migrate to heart transplants where
they prevent the development of alloresponses and promote the
development of Treg (Garcia et al., 2010). Similarly, anti-CD28
antibody-induced rat kidney allograft tolerance leads to the accu-
mulation of MDSCs in the blood. These MDSCs inhibit effector
T cell proliferation in vitro through the activity of inducible nitric
oxide (NO) synthase. Interestingly, however, the adoptive trans-
fer of MDSC in this model does not induce kidney allograft
tolerance.
Regulatory macrophages (Mregs) are a population of
macrophages which produce large amounts of IL-10 and are
able to suppress T cell proliferation in vitro (Fleming and
Mosser, 2011). A population of cells termed “transplant accep-
tance inducing cells” (TAICs) has also been shown to promote
the survival of heart and lung transplants in animal models
(Fandrich et al., 2002a,b,c). TAICs are impure populations of
macrophages contaminated with other leukocytes, whereas Mreg
preparations are a uniform population of macrophages (Hutchin-
son et al., 2012).
CLINICAL TRIALS OF CELLULAR THERAPY FOR
PERIPHERAL REGULATION
Several studies have investigated the use of Treg for the treatment
of GvHD post-HSC transplantation. These studies are paving the
way forTreg therapy in SOT.Trzonkowski et al. (2009) reported the
“ﬁrst-in-man” trial of ex vivo-expanded recipient-derived Treg in
two patients: in one case of chronic GvHD a signiﬁcant alleviation
of symptoms and a reduction of required immunosuppression
was achieved, whereas in one case of severe grade IV acute
GvHD only a transient improvement in symptoms and signs was
reported.
Signiﬁcantly, two major Phase I/II trials have been carried out
at the University of Minnesota and in Italy. Blazar’s group in
Minnesota evaluated the safety proﬁle of human UCB-derived
partially HLA-matched ex vivo-expanded Treg (Brunstein et al.,
2011). The study was designed as a Phase I dose-escalation trial
and reported a reduced incidence of grades II–IV acute GvHD
in the test group of 23 patients compared to 108 identically
treated historical controls not receiving Treg therapy. Doses of
Treg ranged from 1 × 105/kg to 30 × 105/kg and there was no
reported increase in infectious complications. The Italian study
was performed to assess the safety and efﬁcacy of expanded
CD4+CD25+ human nTreg in prevention of GvHD in 28 patients
with high-risk acute leukaemias undergoing HLA-haploidentical
HSC transplants. Patients were also given donor conventional T
cells to enhance immune reconstitution. Treg were derived from
the same HLA-haploidentical donor by apheresis followed by large
scale CD4+CD25+ magnetic bead selection. Despite no GvHD
prophylaxis being given, chronic GvHD did not develop in 26 out
of 28 patients in whom full donor-type engraftment was achieved.
However, in two of the 26 patients acute GvHD of grade II or
above developed, which may be due to these two patients being
given the highest dose of conventional T cells. Patients in the
Italian trial displayed an overall faster post-transplant immune
reconstitution as well as a reduction in the risk of CMV reac-
tivation compared to those not receiving Treg (Di Ianni et al.,
2011). While Brunstein et al. (2011) used UCB-derived Treg,
Di Ianni et al. (2011) used adult expanded Treg. The differ-
ence in efﬁcacy between these two populations on a cell-by-cell
basis is unclear from these studies. However, as discussed earlier,
UCB-derived Treg may contain a higher proportion of “naïve”
CD45RA+ Treg and therefore a greater number of Treg which
may readily proliferate in vivo. This would theoretically repre-
sent an advantage in terms of the cell dose required to prevent
disease.
Other ongoing trials not yet published include one being
conducted by Matthias Edinger at the University Hospital in
Regensburg using CD25hi magnetically isolated non-expanded
Treg infused into post-HSCT recipients (Edinger and Hoffmann,
2011). Trials using Tr1 cells for GvHD are also ongoing at the San
Raffaele Hospital in Milan. Early results have been promising with
no adverse side effects (Roncarolo and Battaglia, 2007; Allan et al.,
2008; Battaglia and Roncarolo, 2011).
Two Phase I/II trials of TAICs assessed the safety of administra-
tion of these cells in 5–12 kidney transplant patients (Hutchin-
son et al., 2008a,b, 2009). The studies aimed to determine
the possibility of immunosuppression withdrawal. The infusion
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of TAICs appeared safe but did not promote tolerance, with
acute rejection developing in several patients on withdrawal of
immunosuppression. Nevertheless, renal functionwasmaintained
in four out of ﬁve patients thatwere tapered to low-dose tacrolimus
monotherapy. Moreover, one patient achieved complete immuno-
suppression withdrawal for 8 months before experiencing a rejec-
tion episode. Moving on from this approach, more uniform Mreg
populations have been trialed in two renal transplant recipients,
leading to a reduction in the required dose of immunosuppres-
sion with good graft function at 3 years post-transplantation
(Hutchinson et al., 2011).
The European Union is currently funding the ﬁrst study for
the evaluation of immunomodulatory cellular therapy in SOT
(www.onestudy.org). The ONE Study, a multicenter Phase I/II
clinical trial, will evaluate the safety and feasibility of various types
of cell therapy including expanded nTreg, Tr1 cells, Mregs, and
tolerogenic DCs in living-donor kidney transplantation. All cen-
terswill utilize a commonadjunctive immunosuppressive protocol
in order to provide a true comparison of the various cellular thera-
pies. Control patients will be transplanted in 2013 and cell therapy
groups in 2014, providing a follow-upperiodof 12months. Table 1
summarizes the concluded and ongoing clinical trials of cellular
therapy.
IMMUNOTHERAPY FOR THE PROMOTION OF TOLERANCE
Treg and effector T cells preferentially employ different intra-
cellular activation pathways. Treg utilize IL-2-dependent STAT-5
(Burchill et al., 2007; Vogtenhuber et al., 2010), whereas effector
T cells utilize the phosphoinositide 3-kinase/Akt/mTOR path-
way (Delgoffe et al., 2009). Rapamycin, an mTOR inhibitor, takes
advantage of this distinction. The beneﬁcial effects of rapamycin
on Treg survival and proliferation have been demonstrated in
vitro and in vivo (Battaglia et al., 2005, 2006b,c; Gao et al., 2007;
Zeiser et al., 2008; Hendrikx et al., 2009). Experimental work in
mouse allograft models has demonstrated that rapamycin inhibits
chronic cardiac allograft rejection and that this effect is poten-
tiated when used in combination with an α-CCR5 antibody (Li
et al., 2009). In this study, an increase in intragraft numbers of
CD4+CD25+foxp3+ Treg was observed. A similar effect has also
been observed clinically, with rapamycin increasing the frequency
Table 1 | Concluded and ongoing clinical studies using cellular therapy for peripheral regulation.
Group Number of
patients
Condition Therapy Outcome
Trzonkowski
(Trzonkowski et al., 2009)
2 HLA-matched
BMT or HSCT
Expanded CD4+CD25+CD127−
donor Treg as treatment for GvHD
Patient 1: Reduction of immunosuppression
Patient 2: Transient clinical improvement
Martelli
(Di Ianni et al., 2011)
28 HLA-haploidentical HSCT Freshly isolated CD4+CD25+
donor Treg
Low incidence of acute and chronic GvHD
with improved immune reconstitution
Blazar
(Brunstein et al., 2011)
23 Double unit unrelated
UCB
Expanded CD4+CD25+ third-party
UCBTreg as prophylaxis against
GvHD
Reduced incidence of grade II-IV GvHD
Trzonkowski
(Trzonkowski et al., 2011)
4 BMT/HSCT Expanded CD4+CD25+CD127−
donor Treg as treatment for GvHD
Alleviation of one case of chronic GvHD, no
effect on acute GvHD
Edinger (Edinger and
Hoffmann, 2011)
9 HSCT Freshly isolatedTreg Ongoing: appears safe and feasible
Roncarolo (Battaglia and
Roncarolo, 2011)
16 HLA-haploidentical HSCT Allostimulated donor Tr1 cells Ongoing: appears safe and feasible
Geissler/Fandrich
(Hutchinson et al., 2009)
1 Deceased donor kidney
transplant
TAICs: feasibility study Immunosuppression reduced to low-dose
tacrolimus therapy, safe and feasible
Geissler/Fandrich
(Hutchinson et al., 2008b)
12 Deceased donor kidney
transplants
TAICs No clear beneﬁt, but safe and feasible
Geissler/Fandrich
(Hutchinson et al., 2008a)
5 Living-donor kidney
transplants
TAICs Four patients tapered to low-dose
tacrolimus monotherapy but higher rate
of early acute rejection
Geissler/Fandrich
(Hutchinson et al., 2011)
2 Living-donor kidney
transplants
Mregs Both patients tapered to low-dose
tacrolimus monotherapy
The One Study
(Wood et al., 2012)
Recruiting Living-donor kidney
transplants
Treg, Mreg, Tr1 cells, tolerogenic
DCs
Ongoing feasibility study
Bluestone/Herold
(Gitelman et al., 2012)
Recruiting
(14 patients)
Treatment of type 1
diabetes
Autologous expanded
CD4+CD25+CD127−Treg
Ongoing feasibility study
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of CD62Lhigh Treg in the peripheral blood of lung transplant recip-
ients (Lange et al., 2010). Experimentally, the adoptive transfer of
a small number of alloantigen-speciﬁc Treg along with low dose
rapamycin treatment has been shown to induce long-term survival
of cardiac allografts in mice (Raimondi et al., 2010). Moreover,
alloantigen-pulsed rapamycin-conditioned DCs have been shown
to promote long-term engraftment of vascularized skin allo-
grafts in rats with an associated expansion of CD4+foxp3+ Treg
(Horibe et al., 2008).
Rabbit anti-murine thymocyte globulin (mATG), a T cell
depleting polyclonal antibody has also shown promise. ATG pro-
motes the generation of Treg (Lopez et al., 2006), and when
combinedwithCTLA4-Ig and rapamycin,mATGshifts the effector
memory T cell-Treg balance in favor of Treg, prolonging the sur-
vival of skin allografts in a fully MHC-mismatched mouse model
(D’Addio et al., 2010).
Interestingly, glucocorticoids may act on human Langerhans
cells to promote a phenotype that favors the induction of Treg
in vitro (Stary et al., 2011). Some patients treated with gluco-
corticoids have increased numbers of dermal FOXP3+CD25+
Treg as well as increased numbers of epidermal Langerhans cells
that display upregulated expression of TGFβ mRNA. However,
there is no clear clinical evidence that ATG or glucocorticoids
are beneﬁcial in terms of increasing Treg numbers in transplant
recipients.
Alemtuzumab may favor Treg survival, with evidence from
one study demonstrating a higher proportional depletion of T
effector cells than Treg (Bloom et al., 2008). However, data in
this study are confounded by the introduction of rapamycin
in patients early after transplantation. Indeed, in a separate
study Treg numbers in alemtuzumab-treated patients remained
low until the late introduction of rapamycin (Trzonkowski et al.,
2008). Interestingly, Bregs have been identiﬁed in renal trans-
plant recipients treated with alemtuzumab (Heidt et al., 2012).
Alemtuzumab induction has been trialed at the University of
Wisconsin for the minimization of immunosuppression (Knech-
tle et al., 2009). In this study, induction with alemtuzumab
together with rapamycin maintenance monotherapy successfully
led to long-term graft survival in nine of 10 patients although
ﬁve patients developed anti-donor antibodies and graft C4d
deposition.
Blockade of the IL-2-CD25 or CD28-CD80/CD86 pathways
is an effective method of producing T cell anergy experimen-
tally (Vincenti, 2008), however these pathways are also essential
for the survival of Treg. Indeed, in mouse models where these
pathways are targeted, there is a reduction in the survival and
function of Treg with an associated exacerbation of autoimmunity
in vivo (Tang et al., 2003; Wing et al., 2008). Clinically, how-
ever, there is no difference in circulating Treg numbers between
renal transplant recipients treated with both belatacept (a second-
generationCTLA-4-related. Ig fusion protein) and basiliximab (an
α-CD25 monoclonal antibody, mAb) compared to those treated
with calcineurin inhibitors (CNIs; Bluestone et al., 2008). Nev-
ertheless, CNIs such as cyclosporine have a detrimental effect
on Treg (Ma et al., 2009; Presser et al., 2009), thus confounding
this observation. In this same study patients receiving belata-
cept displayed higher levels of intragraft FOXP3+ T cells during
acute rejection (Bluestone et al., 2008). Belatacept has proven
to be an effective immunosuppressant, but has not yet demon-
strated any efﬁcacy in the promotion of transplant tolerance
in clinical transplantation. This may be related to the block-
ade of CD80/86-CTLA-4 interaction by CTLA-4.Ig. In a study
investigating a novel CD28 antagonist for use in transplanta-
tion, there was an increase in the number and activity of Treg
in a non-human primate (NHP) renal transplantation model
(Poirier et al., 2010). The beneﬁt of this costimulatory block-
ade, unlike CTLA-4.Ig, is that it allows physiological immune
regulation through CD80/86 to continue (Wing et al., 2008).
The effects α-CD25 mAb on Treg are not entirely clear. In
the study by Bluestone et al. (2008), basiliximab was shown
to deplete all CD25-bearing cells, including Treg. However, in
another study examining daclizumab (a humanized α-CD25
mAb) in cardiac transplant patients, Treg generation in the
periphery was not affected (Vlad et al., 2007). The timing of
treatment with α-CD25 antibodies or CTLA-4.Ig may be of
critical importance and may explain some of the differences
between data from animal and human studies. Early use of
these molecules may target Treg, resulting in deleterious effects
in models dependent on Treg function, whereas later use post-
transplantation may preferentially target activated effector T cells.
Other possibilities include a lower sensitivity of human Treg to
CD28 blockade or the presence of other costimulatory molecules
on human Treg that may substitute for the absence of CD28
costimulation.
While CNIs are normally detrimental to Treg, there is some
evidence that low-dose cyclosporine may enhance the number of
Treg in the skin of patients with atopic dermatitis (Brandt et al.,
2009). This appears to be related to the retained ability of patients
on low-dose cyclosporine to produce IL-2, which is necessary
for Treg survival and expansion (Baumgrass et al., 2010; Brandt
et al., 2010).
Memory T cells present a formidable barrier to the induction
of tolerance in higher mammals (Brook et al., 2006; Ford and
Larsen, 2011). A solution to overcoming this barrier is the use of
immunosuppressants that target memory T cell responses while
promoting the generation of immunoregulatory elements. In this
respect, targeting adhesion molecules such as CD2 or LFA-1 is a
promising strategy. Alefacept, an LFA-3.Ig fusion protein binds to
and polymerizes CD2, leading to selective elimination of memory
T cells. Treatment together with CTLA-4.Ig prevents acute rejec-
tion and allows prolonged engraftment of kidney transplants in
a NHP model (Weaver et al., 2009). Efalizumab, an anti-LFA-1
antibody, initially displayed promise in early clinical trials of islet
transplantation (Badell et al., 2010; Posselt et al., 2010; Setoguchi
et al., 2011). Its use however is no longer possible due towithdrawal
from the market after the development of progressive multifocal
leukoencephalopathy in four patients treated for psoriasis with
efalizumab (Tavazzi et al., 2011).
CONCLUSION
With the trailblazing work of Medawar, clinical tolerance
appeared to be eminently within reach. Yet 70 years on, tol-
erance has been achieved in only a small number of patients
in whom full or mixed chimerism was generated. We propose
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that achieving tolerance in each and every transplant recipient
will require a more complete understanding of the biovariabil-
ity between patients that allows tolerance to be easily induced in
some but not others. The attainment of tolerance in a heteroge-
neous population of transplant recipients may therefore require
a tailored approach, with the balanced use of both central and
peripheral tolerance induction techniques.
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